Samsung Biologics Cuts Biopharma Development Time
A process innovation technology that shortens the biopharmaceutical development period by about 3.5 months, from the previous 13 months to 9.5 months, while maintaining high quality has been unveiled.Samsung Biologics announced on Sep. 28 that it participated in the global bio-industry conference ‘2
Samsung Biologics has unveiled a process innovation technology that shortens the biopharmaceutical development period by approximately 3.5 months, reducing the time from 13 months to 9.5 months while maintaining high quality. The announcement was made at the 2026 BioProcess International (BPI) conference in Boston, USA, where Samsung Biologics participated for the ninth consecutive year.
The company showcased its full-cycle support capabilities, ranging from contract research organization (CRO) to contract development organization (CDO) and contract manufacturing organization (CMO), emphasizing its contract development and manufacturing organization (CDMO) competitiveness. Samsung Biologics also presented a strategy to simultaneously control the quality and efficacy of drugs from the initial stage of cell line development, utilizing the culture process enhancement platform 'S-Tensify.'
James Choi, Executive Vice President of Sales Support at Samsung Biologics, expressed the company's commitment to solidifying its position in the global bio market based on advanced technological capabilities and services.
Brief written by urgent.news from BusinessKorea's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
